Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Open accessThe DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index; 14 of the 80 sources its claims cite were checked for support.
Abstract
Despite Polycystic Ovary Syndrome (PCOS) is a very prevalent disorder among women of reproductive age, there is widespread agreement that until now, no pharmacological options are available to tackle the entire spectrum of clinical manifestations encountered in the clinical practice. Obesity and insulin resistance, which commonly characterized this syndrome, prompted the design of studies investigating the effects of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) in PCOS. Indeed, a very impressive number of randomized controlled clinical trials (RCTs) and systematic reviews provided robust evidence on the effectiveness of GLP-1RA in PCOS as a new, appealing approach, producing both satisfactory and permanent weight loss, and improvement of insulin resistance at the same time. However, most of the subjects included in the RCTs are PCOS patients with obesity/overweight, whereas a portion of PCOS women, which can even reach 50%, might present a lean phenotype. Moreover, some benefits on clinical and metabolic features of PCOS may not have fully emerged due to the low or medium doses employed in the vast majority of the current studies. Thus, pitfalls in the methodology of these studies have led sometimes to misleading results. In addition, some aspects of GLP-1 beyond weight loss, such as preclinical evidence on GLP-1 effects in directly modulating the hypothalamus–pituitary–gonadal axis, or the effects of GLP-1RA on clinical and biochemical expression of hyperandrogenism, still deserve a greater insight, especially in light of a possible therapeutic use in PCOS women independently of obesity. Aim of this review is to further unravel the possible role of GLP-1 in PCOS pathogenesis, tempting to provide additional supports to the rationale of treatment with GLP-1RA in the management of PCOS also independent of weight loss. For this purpose, the outcomes of RCTs investigating in PCOS the anthropometric and metabolic changes have been treated separately to better underpin the effects of GLP-1 RA, in particular liraglutide, beyond weight loss.
Overview
CoChat Summary
TL;DR
This narrative review argues that GLP-1 receptor agonists, especially liraglutide, may benefit PCOS through effects on the hypothalamus–pituitary–gonadal axis and hyperandrogenism beyond weight loss. It summarizes preclinical evidence and RCTs in PCOS, but concludes that most trials enrolled women with obesity/overweight and used low-to-medium liraglutide doses, so additional high-dose RCTs are needed.
Key findings
- Preclinical evidence suggests GLP-1 can modulate the HPG axis centrally and peripherally: GLP-1 stimulated GnRH release in a rodent hypothalamic cell line and increased plasma LH after intracerebroventricular injection in male rats; acute GLP-1 in female rats increased preovulatory LH surge amplitude, estradiol/progesterone secretion, and Graafian follicles/corpora lutea, whereas chronic Exendin-4 reduced Kiss-1 receptor expression, preovulatory LH peak, and delayed puberty.
- In normal-weight PCOS, one study found GLP-1 levels similar to controls until 60 min of a 75-g OGTT but significantly lower after 180 min; another found both fasting and post-meal GLP-1 significantly reduced versus controls.
- In RCTs of PCOS with overweight/obesity, liraglutide 1.8 mg/day for 26 weeks reduced body weight by 5.2 kg (5.6%) and visceral adipose tissue by 18%, reduced liver fat content by 44% and leptin by 20%, increased SHBG, and decreased free testosterone; one 26-week study found no effect on Ferriman Gallwey score.
- Liraglutide 3.0 mg/day for 32 weeks significantly decreased weight, BMI, waist circumference, waist-to-hip ratio, fasting glucose, HOMA-IR, OGTT-derived insulin sensitivity measures, free androgen index, and increased menses occurrence versus placebo; combination metformin plus low-dose liraglutide was sometimes superior for weight/BMI, while one study found liraglutide 3.0 mg/day reduced BMI and waist circumference more than metformin plus liraglutide 1.2 mg/day.
Methods
- Narrative review aiming to assess the possible role of GLP-1 in PCOS pathogenesis and treatment independently of weight loss.
- Evidence reviewed includes preclinical studies on GLP-1 and the HPG axis, two studies of GLP-1 secretion in normal-weight women with PCOS, and RCTs of liraglutide in premenopausal PCOS women with overweight or obesity; Table 1 summarizes the main characteristics and outcomes of the included RCTs.
- Outcomes are discussed separately as anthropometric changes, metabolic changes, biochemical and clinical hyperandrogenism, and body composition/ectopic fat; no systematic search or meta-analysis is described.
Limitations
- The paper states that most RCT participants are PCOS patients with obesity/overweight, whereas lean PCOS may reach 50%, and that low or medium liraglutide doses in most studies may mean some clinical and metabolic benefits have not fully emerged; it calls for additional RCTs, especially with high-dose liraglutide and new-generation GLP-1 RA.
- The paper notes methodological pitfalls in some studies—small sample size, blood sampling on non-specific menstrual cycle days, and very short treatment duration—that may produce misleading results.
- Evident from the text: this is a narrative review without a systematic search or quantitative synthesis; several RCTs come from the same research group and may overlap; clinical hyperandrogenism was often not evaluated (marked NE in Table 1); and no direct studies compare high-dose liraglutide with metformin.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
10 Valid · 1 Not valid · 58 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, hyperinsulinemia is responsible for the increase in the androgen production through both the direct stimulation of insulin receptors and the cross-reaction with Insulin-like Growth Factor-1 (IGF-1) receptors expressed on thecal cells [14].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > Introduction
What the sources say
- Partly supportedcites [14] Pani A, Gironi I, Di Vieste G, Mion E, Bertuzzi F, Pintaudi B (2020) From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: lifestyle and pharmacological management. Int J Endocrinol 2020:6276187. https://doi.org/10.1155/2020/6276187 sourceExperimental — accuracy not yet measured
Our copy supports the first half of the mechanism: the Introduction states insulin 'acts as a cogonadotropin to increase luteinizing hormone (LH)-induced androgen synthesis in theca cells', and Section 3.1 states insulin 'directly stimulates androgen production from ovaries, enhancing the activity of CYP17α' and, with LH, 'acts synergistically on theca cells, increasing androgen biosynthesis'. However, no passage attributes androgen increase to insulin cross-reacting with IGF-1 receptors on thecal cells; the only IGF-related route the paper describes is indirect — insulin inhibits secretion of IGFBP-1, 'resulting in elevated levels of free IGF and androgens'. Searches for 'IGF-1 receptor', 'cross-reaction' and 'insulin-like growth factor receptor' on theca cells returned nothing beyond these passages, so that limb of the claim is unsupported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The insulin resistance in PCOS might also occur independently of body weight, due to inherited post-receptor defects in insulin signalling that affects metabolism and mitotic pathways, not only in classic insulin target tissues, such as skeletal muscle, liver, and adipose tissue, but also in the non-classical target tissues, such as pituitary and ovary [12, 16].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > Introduction
What the sources say
- Partly supportedcites [12] Herman R, Sikonja J, Jensterle M, Janez A, Dolzan V (2023) Insulin metabolism in polycystic ovary syndrome: secretion, signaling, and clearance. Int J Mol Sci. https://doi.org/10.3390/ijms24043140 sourceExperimental — accuracy not yet measured
Our copy supports two of the three components: Section 4 states 'IR in PCOS is the result of a post-receptor abnormality due to a disruption in signal transmission downstream from the insulin receptor' and that this effect is 'more pronounced in PCOS patients than in obese patients', and Section 2 recalls that 'even lean patients with PCOS are insulin resistant' (while also flagging conflicting, less convincing results in lean vs BMI-matched controls). The 'inherited' qualifier is not supported: Section 2 says it 'remains unresolved whether the decreased insulin activity might be due to an intrinsic defect in the insulin signaling pathway, or is instead induced by environmental factors', Section 4 notes genetic studies 'did not yield firm evidence for the genetic etiology of PCOS, which is also influenced by environmental factors', the mechanism summary says 'the exact initial trigger remains to be identified', and Section 3 reports Colilla et al. found 'no evidence of sibling correlation in IR'. The extension to non-classical target tissues is also absent: the tissue-level defects described are skeletal muscle, adipocytes and fibroblasts, with the caveat that 'conflicting results from studies in different human body tissues ... restrict generalization'; ovarian and LH-pulse (pituitary) effects are described only as consequences of hyperinsulinemia (Section 2), not as post-receptor signaling defects in those tissues. (LLM, conf=0.78)
- Supportedcites [16] Zhao H, Zhang J, Cheng X, Nie X, He B (2023) Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res 16(1):9. https://doi.org/10.1186/s13048-022-01091-0 source
All elements of the paraphrase appear in our copy across three sections. The Background states IR occurs in 'more than half of women of normal weight' and that 'IR is independent of and exacerbated by obesity'; the Insulin signal transduction pathway section states that altered serine/tyrosine phosphorylation of insulin receptors and IRS produces 'post-binding defects in insulin signal transduction' (i.e. post-receptor); the Genetics and foetal origin section reports inherited INSR variants (rs2059807, rs1799817, tyrosine-kinase-domain C/T polymorphisms in normal-weight PCOS) and IRS-1 Gly972Arg affecting insulin signalling; and the Hyperinsulinaemia and tissue insulin resistance section states IR 'selectively and mutually affects metabolism or mitotic pathways in classical insulin target tissues (e.g., liver, skeletal muscle, and adipose tissue) and non-classical insulin target tissues (e.g., ovary, pituitary gland)'. The citing sentence is hedged ('might'), which the source states more confidently, so the hedge does not weaken the fit; the only mild caveat is that the review elsewhere says the root cause of PCOS IR 'is largely unknown'. (LLM, conf=0.82)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hyperinsulinemia is closely involved in key steps of the pathogenesis of PCOS and hyperandrogenism [9–12].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > Introduction
What the sources say
- Partly supportedcites [9] Li X, Yang D, Pan P, Azziz R, Yang D, Cheng Y et al (2022) The degree of menstrual disturbance is associated with the severity of insulin resistance in PCOS. Front Endocrinol 13:873726. https://doi.org/10.3389/fendo.2022.873726 sourceExperimental — accuracy not yet measured
The Discussion states that hyperinsulinemia caused by insulin resistance can interfere with follicle development and ovulation, supporting its involvement in PCOS-related processes. It also says more severe insulin resistance can induce excess androgen production, but does not specifically establish that hyperinsulinemia drives hyperandrogenism. (LLM, conf=0.82)
- Partly supportedcites [10] Chen T, Yu Y, Jia F, Luan P, Liu X (2022) The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: a bibliometric analysis. Front Public Health 10:960965. https://doi.org/10.3389/fpubh.2022.960965 sourceExperimental — accuracy not yet measured
The Discussion describes mechanisms linking insulin resistance to increased free testosterone in PCOS, including luteinizing-hormone release and reduced sex-hormone-binding globulin synthesis. It does not specifically identify hyperinsulinemia as the factor involved in those steps, so the claim is supported for insulin resistance but not for its more specific wording. (LLM, conf=0.83)
- Not checked yetcites [11] Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33(6):981–1030. https://doi.org/10.1210/er.2011-1034 source
- Supportedcites [12] Herman R, Sikonja J, Jensterle M, Janez A, Dolzan V (2023) Insulin metabolism in polycystic ovary syndrome: secretion, signaling, and clearance. Int J Mol Sci. https://doi.org/10.3390/ijms24043140 source
Section 2 proposes hyperinsulinemia as an important factor in PCOS development. It also describes how elevated insulin disrupts ovarian function, enhances androgen production, and increases free testosterone. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An in vitro study using GnRH neurons of adult male mice demonstrated that both GLP-1 and Ex4 might excite GnRH neurons, either directly or indirectly by modulating the nitric oxide (NO) and endocannabinoid pathways that control the presynaptic excitatory GABA-ergic inputs to GnRH neurons [36].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > Glucagon-like peptide-1 and HPG axis > HPG axis central effects: hypothalamus and pituitary
What the sources say
- Supportedcites [36] Farkas I, Vastagh C, Farkas E, Balint F, Skrapits K, Hrabovszky E et al (2016) Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways. Front Cell Neurosci 10:214. https://doi.org/10.3389/fncel.2016.00214 source
The Materials and Methods (Animals; Brain Slice Preparation and Recordings, page unavailable) describe recordings from hypothalamic slices of adult male mice. The Abstract reports that Exendin-4 increased GnRH-neuron firing and excitatory GABAergic currents; the Discussion (The NO and Endocannabinoid Retrograde Signaling Pathways are Simultaneously Involved, page unavailable) interprets the findings as a direct action of a GLP-1 agonist on GnRH neurons through NO and endocannabinoid signaling. The paper thus supports the hedged claim about GLP-1 and its analog Ex4, although Ex4 was the compound administered in the recordings. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the first study, the authors did not find any significant difference in biochemical hyperandrogenism in both intra and inter-groups, despite the significant improvement in anthropometric parameters in the group treated with liraglutide [57].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > GLP-1 in normal-weight PCOS > Biochemical and clinical hyperandrogenism
What the sources say
- Supportedcites [57] Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 8:32. https://doi.org/10.1186/s13048-015-0161-3 source
The Methods (Study design) confirm the exact regimens the claim attributes to this trial: liraglutide 1.2 mg QD s.c. versus metformin 1000 mg BID in obese PCOS women. The Results (Endocrine parameters) state that the only androgen changes were in the roflumilast arm ('a significant total T and Free Androgen Index (FAI) reduction were noted in ROF arm'), and that 'No statistically significant differences were found in free T, SHBG, androstenedione, DHEAS (Table 2), or in LH and FSH, neither over time nor when analyzing it separately by therapeutic arm' — i.e. no intra- or inter-group effect for the liraglutide-versus-metformin comparison; Table 2 lists interaction p-values only for ROF (Total T I(R=0.050), FAI I(R=0.016)) with no L entry. The accompanying concession is also supported: the Abstract/Results report LIRA superior to MET in weight (p=0.022), BMI (p=0.020) and waist circumference (p=0.007). (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 2 with their cited sources checked
Create a free account to see all 81 claims and to verify the 66 references still open.
- It may state two separate claims as one. 44
- The quote only partly states this claim. 2
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Available evidence showed that both OD liraglutide 1.8 mg and 3.0 mg were associated with higher levels of SHBG, lower free androgen index and increased menstrual frequency vs. placebo95.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [95]
In the citing paper
“Several RCT investigated the role of liraglutide, alone or in combination with metformin, in women with PCOS and overweight or obesity, confirming its beneficial effect on anthropometric and metabolic features95”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > Introduction
“recent and very exhaustive reviews on the available clinical trials on glucagon-like peptide 1 receptor agonists (GLP-1RA) in PCOS [21, 23, 24].”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > References
“23. Quigley K Goya R Meites J Rejuvenating effects of 10-week underfeeding period on estrous cycles in young and old rats Neurobiol Aging 1987 8 3 225 232”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > GLP-1 in normal-weight PCOS > RCTs of liraglutide in PCOS
“Nondiabetic women with obesity who had lost ≥ 5% of body weight during pre-treatment with MET for at least 6 months”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > GLP-1 in normal-weight PCOS > Anthropometric changes
“nondiabetic women with obesity and PCOS who had lost < 5% body weight during pre-treatment with metformin”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > GLP-1 in normal-weight PCOS > RCTs of liraglutide in PCOS
“Jensterle et al. 2015 [60]”
§ Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? > References
“60. Jensterle M Goricar K Janez A Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study Exp Ther Med 2016”
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Research works printed but not linked: 1
- Helvaci N, Yildiz BO (2023) Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opin Pharmacother 24(1):105–120. https://doi.org/10.1080/14656566.2022.2108702 · DOI · Paper page
Cited by
Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
Mittal, R., Prasad, K., Lemos, J. R. N., Arevalo, G., & Hirani, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052320 · Cited by 181
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
“Several RCTinvestigated the roleofliraglutide,aloneor in combination with metformin, in women with PCOS and overweight or obesity, con fi rming its bene fi cial effect on anthropometric and metabolic features 95 ; however, changes in menstrual cyclicity and hyperandrogenism were rarely assessed.”
InfluentialBarrea, L., Verde, L., Annunziata, G., Camajani, E., Caprio, M., Šojat, A. S., Marina, L., Guarnotta, V., Colao, A., & Muscogiuri, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02169-2 · Cited by 35
“Weight loss reduces insulin, sex hormone-binding globulin (SHBG), and estrogen levels; moreover, excess weight before conception is a major risk factor for fertility outcomes and it is well established that weight loss improves fertility in women with overweight and obesity [137, 147].”
BackgroundSelf-citationWang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 46
“147 Beyond being an appetite suppressant, Liraglutide has recently been explored for its potential to induce visceral fat loss in humans.”
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“Liraglutide has been evaluated in several small RCTs in women with PCOS, with beneficial effects seen in terms of: body weight and other weight-related outcomes; metabolic changes including HbA 1c , FPG, and HOMA-IR; endocrine changes; menstrual pattern; and body composition [124].”
Metadata
- Authors
- Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S.
- Affiliations
- Federico II University Hospital (IT)
- Pegaso University (IT)
- Corresponding author
- Pugliese, G.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2023-04-24
- Volume
- 46
- Issue
- 9
- Pages
- 1761-1774
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC10372121
- OpenAlex
- W4366819379
- Cited by
- 29
- References
- 67
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 4 · 2023: 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Università degli Studi di Napoli Federico II
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, polycystic ovary syndrome, GLP-1 receptor agonists, weight loss, insulin resistance, hyperandrogenism, hypothalamic-pituitary-gonadal axis, PCOS pathogenesis
- MeSH terms
- Liraglutide, Body Weight, Female, Humans, Insulin Resistance, Obesity, Polycystic Ovary Syndrome, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? https://app.cochat.ai/papers/10.1007/s40618-023-02084-6
- The paper
- Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023). Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-023-02084-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
